Company Overview of SteadyMed Therapeutics, Inc.
SteadyMed Therapeutics, Inc. engages in the development and commercialization of prefilled, size efficient, disposable, subcutaneous liquid drug delivery systems. Its PatchPumps technology is customized to deliver liquid drugs, including biologics with a range of volumes and viscosities. The company was founded in 2005 and is based in San Ramon, California.
2410 Camino Ramon
San Ramon, CA 94583
Founded in 2005
Key Executives for SteadyMed Therapeutics, Inc.
Chief Executive Officer and Director
Co-Founder and Vice President of Business Development
Vice President of Operations
Chief Technical Officer and Executive Vice President of R&D
Compensation as of Fiscal Year 2014.
SteadyMed Therapeutics, Inc. Key Developments
SteadyMed Therapeutics, Inc. Announces Management Appointments
Jun 10 13
SteadyMed Therapeutics, Inc. announced that Peter Noymer has joined the company as EVP of R&D and CTO, and Rick White has joined as VP BD and Commercial Operations. Peter is responsible for completing the development of the company's PatchPump(R) parenteral drug delivery technology as well as clinical and regulatory affairs for SteadyMed's PatchPump drug product to treat Pulmonary Arterial Hypertension (PAH). Previously, he was VP of Product R&D at Alexza Pharmaceuticals, where he worked on several development programs on combination products for novel therapies, including Adasuve(R), the first inhalable treatment for acute agitation. Prior to that, he held senior management positions at Aradigm Corporation and was a Visiting Assistant Professor at Carnegie Mellon University. Rick is responsible for both Business Development activities related to the licensing of PatchPump technology to BioPham companies, for delivery of high volume biologic products, as well as the initiation of pre-commercial activities relating to PatchPump drug product to treat PAH. Most recently Rick was VP of BD & Marketing at Ligand Pharmaceuticals where he was successful in executing drug delivery technology licenses with both large and small Pharma companies, as well as multiple product licensing initiatives.
Square 1 Bank Provides $3 Million Term Loan to SteadyMed Therapeutics, Inc
Apr 8 13
Square 1 Bank announced that it has provided a $3 million term loan to new client, SteadyMed Therapeutics, Inc. Proceeds will be used to provide working capital to SteadyMed while it continues to develop its proprietary PatchPump technology and complete clinical trials for FDA Approval.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries